Bristows
  • Expertise

    Core sectors

    • Life sciences
    • Technology
    • Brands

    Litigation & dispute resolution

    • Patent litigation
    • Brands, designs & copyright
    • Commercial & technology disputes
    • Competition litigation
    • Data breaches & cyber security
    • SEP/FRAND disputes
    • Media disputes
    • IT disputes
    • Arbitration

    Transactions

    • Corporate & financing
    • IT & digital
    • Commercial & IP transactions
    • Employment
    • EU & UK merger control
    • Real estate
    • Tax

    Regulatory & advisory

    • Competition advice & investigations
    • Data protection & privacy
    • Life sciences regulatory
    • TM & design portfolio management
    • Freedom to operate
    • Advertising & marketing
    • Charities & not-for-profit
  • Viewpoint
    • Articles
    • News
    • Publications
    • Events
    • Inquisitive minds
  • People
  • Careers
    • Trainees
    • Current opportunities
    • Inclusion and Diversity
    • Life at Bristows
  • About us
    • Our values
    • A reputation for firsts
    • International reach
    • Awards
    • Corporate responsibility
    • Alumni
    • Compliance information
    • GDPR
  • Contact
toggle mobile menu
  1. Home
  2. On the Pulse
  3. How the CJEU has interpreted “protected” in the SPC regulation

How the CJEU has interpreted “protected” in the SPC regulation

21.04.2017

Bristows partner Brian Cordery and associate Steven Willis look at how the CJEU has approached Article 3(a) of the SPC Regulation.

Read full article on the Managing IP website.

Brian Cordery

Author

image description

Credentials

Practice areas

    What others say

    • Full profile
    • Back to people results

    Share

    Related news
    • UK MDR amending legislation heralds arrival of new medical device framework
      24.05.2023
    • DNA sequencing by synthesis patents held valid and infringed
      03.05.2023
    • Under the antitrust spotlight: (mis)use of patents in the pharma sector
      12.04.2023
    • Updates to EU and UK competition authority guidance – why the biopharma sector should sit up and take note
      05.04.2023
    • Arrow declarations – is there a limit to their availability?
      29.03.2023
    • Will we ever see a UKCA mark for medical devices?
      28.03.2023
    Back to articles
    • twitter
    • facebook
    • linkedin
    • youtube
    (SRA Number 591711)
    Bristows LLP
    London:

    100 Victoria Embankment
    London EC4Y 0DH
    T +44 20 7400 8000
    DX 269

    Brussels:

    Avenue des Arts 56 
    1000 Bruxelles 
    Belgium 
    T +32 2 808 7500 

    • Expertise
    • Viewpoint
    • People
    • Careers
    • About us
    • Contact
    RSS feeds
    • News and publications
    • Events and seminars
    Other links
    • Bristows Trainees site
    • On the Pulse
    • The Cookie Jar
    • The CLIP Board
    • UPC
    Other languages
    • Chinese
    • Japanese
    • Accessibility
    • Compliance information
    • Cookie policy
    • Modern slavery act
    • Terms of use
    2021 Bristows LLP Website by Itineris